Anti-Cancer Actions of Denosumab

Denosumab works by binding to and inhibiting receptor activator of nuclear factor-κB ligand (RANKL). Through this mechanism, it can inhibit any cause of bone destruction and thus shows great efficacy in high-turnover osteoporosis. The FREEDOM (Fracture Reduction Evaluation of Denosumab in Osteoporos...

Full description

Saved in:
Bibliographic Details
Published in:Current osteoporosis reports 2011-12, Vol.9 (4), p.173-176
Main Authors: Iqbal, Jameel, Sun, Li, Mechanick, Jeffrey I., Zaidi, Mone
Format: Article
Language:English
Subjects:
Animals
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Antineoplastic Agents - therapeutic use
Denosumab
Disease Models, Animal
Epidemiology
Epidemiology and Pathophysiology (Mone Zaidi and Jeffrey I. Mechanick
Female
Humans
Mammary Neoplasms, Experimental - drug therapy
Medicine
Medicine & Public Health
Mice
Orthopedics
Osteoporosis, Postmenopausal - drug therapy
RANK Ligand - antagonists & inhibitors
Section Editors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Denosumab works by binding to and inhibiting receptor activator of nuclear factor-κB ligand (RANKL). Through this mechanism, it can inhibit any cause of bone destruction and thus shows great efficacy in high-turnover osteoporosis. The FREEDOM (Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months) trial established the effectiveness of denosumab as a therapy for menopausal bone loss, whereas several newer trials have found denosumab to have shown denosumab to be beneficial in preventing skeletal events from bone metastases. This review highlights the potential novel anti-cancer mechanisms of action of denosumab in mammary tumors.
ISSN:1544-1873
1544-2241
DOI:10.1007/s11914-011-0069-9